ClinicalTrials.gg

Program

zilebesiran

Also written as “Zilebesiran” and “ALN-AGT01”.

Its studies are mostly in Hypertension, led by Alnylam Pharmaceuticals.

Furthest: phase 3, since Sep 12, 20255 company-led studies, 1 open or runningNext primary completion: Sep 23, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alnylam Pharmaceuticals51 open or runningphase 3since Sep 12, 2025Apr 29, 2019Sep 23, 2030phase 3 · NCT07181109
  • Named in hoffmann la roche’s own pipeline as RG6615 zilebesiran (Alnylam), phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Hoffmann-La Roche.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2019First study: phase 1 study in HypertensionFirst studyNCT03934307 · 124 enrolled · United Kingdom
  2. Jun 14, 2021Phase 2 study in HypertensionNCT04936035 · 394 enrolled · United States, Canada, Puerto Rico and more
  3. Feb 15, 2024Phase 2 study in HypertensionNCT06272487 · 375 enrolled · United States, Australia, Canada and more
  4. May 15, 2024Phase 2 study in HypertensionNCT06423352 · 36 enrolled · Japan
  5. Sep 12, 2025Phase 3 study in HypertensionNCT07181109 · 11,000 planned · United States, Argentina, Australia and more

Ahead

  1. Sep 23, 2030Primary completion: phase 3 study in HypertensionNCT07181109

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07181109Hypertension · United States, Argentina, Australia and more3RecruitingSep 23, 203011,000
NCT06423352Hypertension · Japan2CompletedJul 17, 202536
NCT06272487Hypertension · United States, Australia, Canada and more2CompletedJun 19, 2025375
NCT04936035Hypertension · United States, Canada, Puerto Rico and more2CompletedApr 4, 2023394
NCT03934307Hypertension · United Kingdom1CompletedApr 20, 2022124

How it is read

Names in the registry

  • “Zilebesiran”, 3 entries
  • “ALN-AGT01”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
zilebesiran (Alnylam Pharmaceuticals): development program | ClinicalTrials.gg